#monoclonal antibody

Immunological Applications

Denosumab targets which pathway?

Skeletal remodeling balance controlled by triad RANKL-RANK-osteoprotegerin discovered late 1990s as final common pathway for osteoclastogenesis. RANKL encoded by TNFSF11 gene chromosome 13q14 expressed as type II membrane protein and cleaved soluble form by metalloproteinases TACE from osteoblasts, osteocytes responding to parathyroid hormone, active vitamin D3, and inflammatory cytokines interleukin-1, tumor necrosis factor, and activated T cells expressing RANKL contributing to inflammatory bone loss. Binding to RANK receptor TNFRSF11A on monocyte-macrophage precursors belonging to tumor nec

Ref: Boyle et al Nature 2003 423:337 RANKL RANK OPG axis; Denosumab FDA label TNFSF11 neutralization osteoporosis.

View Details

Immunological Applications

Omalizumab is used in treatment of:

Severe persistent allergic asthma pathophysiology centers on Th2 polarization with interleukin-4 and interleukin-13 driving class switch recombination from IgM to IgE mediated by AID and germline ε transcription in B cells within bronchial associated lymphoid tissue. Secreted IgE circulates at low concentration 150 ng per ml but binds extremely high affinity FcεRI alpha chain Kd 10^-10 M on mast cells and basophils through Cε3 domain interaction, sensitizing them for months despite short serum half-life two days. Upon re-exposure to perennial aeroallergen such as Dermatophagoides pteronyssinus

Ref: GINA 2023 severe asthma Omalizumab IgE; Holgate Nat Rev Immunol anti-IgE Cε3 blocks FcεRI downregulation.

View Details

Immunological Applications

Rituximab targets which antigen?

MS4A1 gene on chromosome 11q12.2 encodes CD20 differentiation antigen, 33 to 37 kDa tetra-spanning membrane phosphoprotein with both N and C termini intracellular, four transmembrane helices forming tetrameric oligomer functioning as store-operated calcium channel component modulating B cell receptor induced calcium flux via interaction with calcium release-activated calcium modulator ORAI1. Expression tightly regulated during ontogeny: absent on hematopoietic stem cells and early pro-B, appears at late pro-B stage after productive immunoglobulin heavy chain rearrangement, persists through mat

Ref: NCBI Gene MS4A1 CD20 tetra-span; Janeway Immunobiology CD20 calcium channel rituximab ADCC CDC.

View Details

Immunological Applications

Trastuzumab (Herceptin) is used in treatment of:

Alemtuzumab humanized IgG1 mAb 150 kDa directed CD52 glycopeptide 21-28 kDa GPI-anchored highly expressed 500k copies normal malignant B T lymphocytes monocytes macrophages eosinophils dendritic cells but absent HSC permitting immune reconstitution after depletion absent neutrophils limiting neutropenia. CD52 function incompletely understood proposed T-costimulation binding Siglec-10 inhibitory modulating migration L-selectin. Binding clusters GPI protein lipid rafts inducing proximity Fc enabling C1q multivalent binding activating classical complement C4 C2 cleavage forming C3 convertase C4b2

Ref: Hale 1983 Transplantation Alemtuzumab CD52 Expression; FDA Campath Lemtrada Label CD52 Depletion; Janeway CD52 Depletion Reconstitution Chapter 14.

View Details

Basic Applied Biology

Rituximab targets antigen:

Rituximab represents first chimeric anti-cancer monoclonal antibody approved 1997 targeting CD20, a 33 to 37 kDa non-glycosylated tetra-span membrane phosphoprotein encoded by MS4A1 gene on chromosome 11q12 expressed on pre-B through mature B lymphocytes but absent on hematopoietic stem cells, pro-B cells and terminally differentiated plasma cells. Protein architecture comprises four transmembrane domains with short intracellular termini and two extracellular loops accessible for antibody binding. Physiologic function involves regulation of calcium flux through modulating B cell receptor signa

Ref: Maloney et al. Blood 1997 Rituximab ideal target; Reff et al. CD20 biology; PubMed review CD20 therapeutic target.

View Details

Cell Signaling ELR Pathways - I

Trastuzumab (Herceptin) targets

HER2, is consistent with established principles of cell signaling, receptor pharmacology and cellular regulation. Experimental measurements of binding parameters, genetic loss-of-function studies and pharmacological interventions all converge on the same interpretation. Related options address neighboring concepts but do not satisfy the precise criterion stated in the question.

Ref: NCERT Biology Class 11–12 Alberts et al Molecular Biology of the Cell Lodish et al, Molecular Cell Biology Cooper & Hausman, The Cell Abbas et al., Cellular and Molecular Immunology (for immunology sections)

View Details